Letters sent to healthcare professionals in June 2017

Letters were sent about Arsenic Trioxide (Trisenox), Uptravi鈻� (selexipag), DepoCyte (cytarabine), Cinryze鈻� (C1 esterase inhibitor [human]), and Clexane (enoxaparin sodium).

From:
Medicines and Healthcare products Regulatory Agency
Published
20 July 2017
Therapeutic area:
Cancer, Cardiovascular disease and lipidology, Haematology and oncology, Immunology and vaccination and Infectious disease
Show 3 more
Paediatrics and neonatology, Respiratory disease and allergy, and Urology and nephrology

In June 2017, the following letters were sent to relevant healthcare professionals:

  • Arsenic Trioxide (Trisenox) 1 mg/mL concentrate for solution for infusion:

  • Uptravi鈻� (selexipag):

  • Cinryze鈻� (C1 esterase inhibitor [human]): recommendations to prescribers in view of a

  • DepoCyte (cytarabine):

  • Clexane (enoxaparin sodium):

Article citation: Drug Safety Update volume 10 issue 12, July 2017: 4.

Updates to this page

Published 20 July 2017